Concertai and neogenomics announce new ai software-as-a-service solution for hematology clinical research

Cambridge, mass.--(business wire)--concertai and neogenomics (nasdaq: neo) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. cto-h provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. cto-h is a major outcome of the collaboration jointly announced on jan. 8, 2024, and the more recent joint research completed and scheduled f.
NEO Ratings Summary
NEO Quant Ranking